Exelixis, Inc. ( EXEL) - Stock Earnings
EXEL Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Nov. 3, 2026, midnight | — / — | — | — / — | — |
EXEL Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q4 | 244.5 million USD | 598.7 million USD |
| 2026Q1 | 210.5 million USD | 610.8 million USD |
| 2026Q2 | 212.1 million USD | 628.7 million USD |
| 2026Q4 Est. | — | — |
| 2027Q1 Est. | — | — |
| 2027Q2 Est. | — | — |
EXEL Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 207.8 million USD | 1.8 billion USD |
| 2024 | 521.3 million USD | 2.2 billion USD |
| 2025 | 782.6 million USD | 2.3 billion USD |
| 2026 Est. | — | — |
EXEL
Price: $59.86
Earnings Per Share: 3.18 USD
P/E Ratio: 16.14
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 986798
Ebitda: 84.9 millionMarket Capitalization: 14.8 billion